AI-generated analysis. Always verify with the original filing.
Travere Therapeutics, Inc. filed an 8-K on February 19, 2026, disclosing results of operations under Item 2.02 with Exhibit 99.1 press release attached. The filing includes references to analyst consensus EPS context for the period.
Event Type
Disclosure
Mandatory
Variant
8-K
, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Excha
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Travere Therapeutics, Inc. dated February 19, 2026. 104 Cover Page